Skip to main content
. 2021 Jun 28;12:680188. doi: 10.3389/fimmu.2021.680188

Figure 4.

Figure 4

S protein IgG subclasses responses in non-intubated or intubated patients with or without remdesivir (RDV) treatment. (A) IgG1, IgG2, IgG3, and IgG4 responses were analysed by screening plasma samples of non-intubated COVID-19 patients with RDV (n = 21) or without RDV (n = 17) treatment, and (B) intubated COVID-19 patients with RDV (n = 6) or without RDV (n = 10) treatment at 1:100 dilution against cells expressing the full-length SARS-CoV-2 spike protein, with healthy donors screened in parallel (n = 22). The ratio of combined IgG2 and IgG4 to combined IgG1 and IgG3 response (IgG2/4/IgG1/3) in RDV-treated patients with or without intubation before and after treatment and also in non-RDV-treated patients at matched time point 1 and 2 were computed and the increase in the ratio from the first to the second time point was plotted. Statistical analyses were performed with Mann Whitney U test (*P < 0.05).